2
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Dermatologic
1
Conditions
Melanoma
16
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
11
Carcinoma, Renal Cell
6
Kidney Neoplasms
4
Leukemia, Myeloid, Chronic-Phase
3
Carcinoma, Hepatocellular
3
Unspecified Adult Solid Tumor, Protocol Specific
2
Polycythemia Vera
2
Ovarian Neoplasms
2
Neoplasm Metastasis
2
Lymphoma
2
Leukemia
2
Hepatitis B, Chronic
2
Fallopian Tube Neoplasms
2
Brain Neoplasms
2
Uveal Melanoma
1
Thrombocytosis
1
Thrombocythemia, Essential
1
Squamous Cell Carcinoma of Head and Neck
1
Skin Neoplasms
1
Sezary Syndrome
1
Recurrence
1
Primary Myelofibrosis
1
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
1
Precancerous Conditions
1
Osteosarcoma
1
Neurofibromatosis 1
1
Neurofibroma, Plexiform
1
Neurofibroma
1
Neoplasms
1
Interventions
Amifostine
19
Cisplatin
15
Radiotherapy
13
Etoposide
10
Cyclophosphamide
9
Carboplatin
8
Paclitaxel
7
Filgrastim
7
Drug Therapy
5
Cytarabine
5
apatinib
4
Methotrexate
4
sodium thiosulfate
3
Methylprednisolone
3
Gemcitabine
3
Docetaxel
3
sargramostim
2
pegfilgrastim
2
glucarpidase
2
etoposide phosphate
2
denileukin diftitox
2
camrelizumab
2
Voriconazole
2
Vincristine
2
Social Determinants of Health
2
Pyridoxine
2
Peripheral Blood Stem Cell Transplantation
2
Nivolumab
2
Mitoxantrone
2
Melphalan
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Drug-Related Side Effects and Adverse Reactions
×
peginterferon alfa-2b
×
Clear all
NCT00221702
2010-10-13
EADO
University Hospital, Bordeaux
Phase 3
Completed
898 enrolled